Amgen Expands Hep C Agreement With Three Rivers To China
This article was originally published in PharmAsia News
SHANGHAI - Three Rivers Pharmaceuticals has signed a definitive licensing agreement with Amgen to acquire further commercial rights, including China, for the hepatitis C drug Infergen, the company announced Sept. 1
You may also be interested in...
SHANGHAI - China's hepatitis C virus drug market will grow to $150 million by 2012, according to a report released in September by Decision Resources
MUMBAI - Jubilant Biosys, a subsidiary of Indian contract research and manufacturing services provider Jubilant Organosys, has entered into a drug discovery partnership with Amgen to develop a portfolio of new drugs across various therapeutic areas
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion